Latest news with #radiopharmaceuticals
![Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting](/_next/image?url=https%3A%2F%2Fdims.apnews.com%2Fdims4%2Fdefault%2Fdcac1a4%2F2147483647%2Fstrip%2Ftrue%2Fcrop%2F700x394%2B0%2B28%2Fresize%2F1440x810!%2Fquality%2F90%2F%3Furl%3Dhttps%253A%252F%252Fassets.apnews.com%252F90%252F29%252F4e3c1cc7446089a9101a7bdff4c8%252Fdefaultshareimage-copy.png&w=3840&q=100)
![Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fapnews.com.png&w=48&q=75){kind=small}
Associated Press
30-05-2025
- Business
- Associated Press
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ('Perspective' or the 'Company') (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. This Phase 1/2a clinical trial is a multi-center open-label dose escalation and dose expansion study ( identifier NCT05636618 ) of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapy (RPT) and whose tumors have shown radiological evidence of disease progression in the 12 months prior to enrollment. Updated interim efficacy data were presented for two patients in Cohort 1 and seven patients in Cohort 2 with a data cut-off date of April 30, 2025. These patients were enrolled for dose limiting toxicities observations. Results with a data cut-off date of January 10, 2025 from these patients were previously presented as a poster at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) in January 2025. Cohort 2 was reopened for enrollment in August 2024, and through April 30, 2025, a further 33 patients were enrolled in Cohort 2 and had received at least one treatment. Safety data were presented at the ASCO Annual Meeting for all 42 patients who had received at least one treatment with [212Pb]VMT-α-NET. A modest number of patients experienced low grade hematologic toxicities. Observations of lymphocyte count decrease were generally low grade, with three events at Grade 3 and none at Grades 4 or 5. Increases in blood creatinine levels were all at Grade 1. No dysphagia or serious renal complications were reported. Seven out of nine patients in Cohorts 1 and 2 continued to experience disease control and remained in study. One patient experienced stable disease for 48 weeks after their first dose prior to experiencing progressive disease. One patient was previously reported to have progressive disease after one dose under RECIST v1.1, by unambiguous progression of non-target lesions. The first patient who experienced a confirmed objective response remained in response for over 10 months and in study. This patient received the first two [212Pb]VMT-α-NET doses at administered dose of 5.0 mCi (equivalent to 84.6 µCi/kg), then received the remaining two doses at the next lower activity level of 2.5 mCi (equivalent to 42.4 µCi/kg). Two patients experienced initial responses after the end of their treatment periods as of the data cut-off date for the previous data presentation at ASCO-GI. Those responses have since been confirmed in subsequent scans. They remained in response and in study. These patients received four doses of 5.0 mCi (equivalent to 68.7 µCi/kg and 31.7 µCi/kg) of [212Pb]VMT-α-NET. A fourth patient was observed to experience an initial (unconfirmed) response in the seventh scan at 48 weeks after their first dose, which was the third scan conducted after the end of their treatment period. This patient received four doses of 5.0 mCi (equivalent to 49.1 µCi/kg) of [212Pb]VMT-α-NET. As stated in our August 12, 2024 business update for the second quarter of 2024, the observation period was completed for DLTs in seven patients enrolled in Cohort 2 during the second quarter of 2024. With no DLTs observed and minimal toxicity overall, the Safety Monitoring Committee (SMC) recommended proceeding with dose escalation and enrolling additional patients at 5 mCi to better understand efficacy and safety. Based on interactions with the U.S. Food and Drug Administration (FDA) prior to the initiation of patient dosing in this study in late 2023, the decision to dose patients in the next cohort will follow consultation and alignment with the FDA. "[212Pb]VMT-α-NET is emerging as an exciting potential treatment option for patients with progressive NETs, with continued durability of anti-tumor activity at the dose level used in Cohort 2 and a favorable tolerability profile seen so far,' said Vikas Prasad, MD, Associate Professor of Radiology, Mallinckrodt Institute of Radiology, Siteman Cancer Center, Washington University School of Medicine. 'I am eager to find more treatments to help my patients fight hard against their disease and return to their normal lives. I look forward to continuing to evaluate [212Pb]VMT-α-NET as a new option to help my patients, by participating in this study.' Markus Puhlmann, Chief Medical Officer of Perspective, commented, 'We are encouraged by the exciting overall clinical profile already observed at the dose level used in Cohort 2. The robust participation in the re-opened Cohort 2 in this dose finding study of [212Pb]VMT-α-NET enables us to learn more about how [212Pb]VMT-α-NET can benefit patients and fit into the current treatment paradigm. We plan to submit longer safety follow-up data for all patients enrolled in the study and preliminary efficacy data for a subgroup for presentation at a scientific congress in the second half of this year. In keeping with the commitment we made to the FDA prior to the start of dosing in this study, we are engaging with the FDA as we wish to continue to pursue dose finding for [212Pb]VMT-α-NET. An update will be provided once alignment is reached with the agency.' Thijs Spoor, Chief Executive Officer of Perspective, commented, '[212Pb]VMT-α-NET is progressing expeditiously as one of three potential new medicines in clinical development based on our next generation targeted radiopharmaceutical technology platform. We continue to evaluate opportunities to enhance our operations and infrastructure so we can support patient demand for all of our programs.' Perspective will webcast a conference call on Monday, June 2, 2025 at 8:00 am ET to discuss the data presented at the ASCO Annual Meeting. Webcast details are available on the Events page of the Company's website. Dr. Prasad will participate, along with members of Perspective's management team. A live question and answer session will follow the formal presentation. About [212Pb]VMT-α-NET Perspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label dose escalation, dose expansion study ( identifier NCT05636618 ) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies (RPT). Results with a data cut-off date of January 10, 2025 from the first nine patients enrolled into Cohorts 1 and 2 of the study were previously presented as a poster at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium ( ASCO-GI ) in January 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 patients enrolled after the cohort reopened and through April 30, 2025, will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Neuroendocrine Tumors Neuroendocrine tumors form in cells that interact with the nervous system or in glands that produce hormones. They can originate in various parts of the body, most often in the gut or the lungs and can be benign or malignant. Neuroendocrine tumors are typically classified as pancreatic neuroendocrine tumors or non-pancreatic neuroendocrine tumors. According to it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year. Importantly, neuroendocrine tumors are associated with a relatively long duration of survival compared to other tumors and as a result, there are over 170,000 people living with this diagnosis.1 About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This 'theranostic' approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'estimate,' 'believe,' 'predict,' 'potential,' or 'continue' or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the potential for [212Pb]VMT-α-NET to be a treatment option for and benefit patients with progressive NETs with durable anti-tumor activity and a favorable tolerability profile, including at the dose level administered to patients in Cohort 2 of the Company's [212Pb]VMT-α-NET study; the Company's belief that robust participation in the re-opened Cohort 2 in this dose finding study of [212Pb]VMT-α-NET will enable it to learn more about how [212Pb]VMT-α-NET can benefit patients and fit into the current treatment paradigm; the potential for treatments such as [212Pb]VMT-α-NET to help patients fight hard against their disease and return to their normal lives; the Company's clinical development plans and the expected timing thereof; the expected timing for availability and release of additional data from the Company's clinical trials; the Company's anticipated timing and expectations regarding regulatory communications, requests, interactions, submissions, alignment, and approvals, including the Company's expectation that it will reach an alignment with the FDA on dose-finding for [212Pb]VMT-α-NET; the Company's activities and plans to pursue dose escalation for its Phase 1/2a clinical trial of [212Pb]VMT-α-NET; the Company's plans to enhance its operations and infrastructure to support patient demand for all of its programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its 'theranostic' approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the 'SEC'), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR: Annie J. Cheng, CFA [email protected] Russo Partners, LLC Nic Johnson [email protected] 1 Wu P, He D, Chang H, Zhang X. Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA. Endocr Connect. 2023;12(12):e230331. Published 2023 Nov 23. doi:10.1530/EC-23-0331.
Yahoo
27-05-2025
- Business
- Yahoo
ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds
Debt capital to support commercial readiness and potential U.S. launch of n.c.a. 177Lu-edotreotide (ITM-11), following positive Phase 3 results Flexible funding structure enables continued advancement of ITM's targeted radiopharmaceutical pipeline and leading radioisotope manufacturing business Garching / Munich, Germany, May 27, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a debt financing agreement for up to USD 262.5 million from funds managed by Blue Owl Capital, Inc ('Blue Owl'). The capital will be used to prepare for commercial readiness and potential market launch of the company's lead candidate, n.c.a. 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). ITM-11 recently met the primary endpoint in the COMPETE Phase 3 study as a potential treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM plans to submit a New Drug Application (NDA) for this asset to the U.S. FDA in 2025. In addition, the company will continue to accelerate the development of its innovative targeted radiopharmaceutical pipeline and the scale-up of Actinium-225 manufacturing through its joint venture, Actineer. Under the terms of the agreement, ITM will receive USD 140 million upon closing and can exercise additional tranches. Further details of the agreement have not been disclosed. 'Blue Owl is a highly regarded investor with a deep appreciation for the potential of radiopharmaceuticals, and we see their debt capital for ITM as a validation of our position as a cornerstone of the radiopharmaceutical industry,' said Dr. Andrew Cavey, CEO of ITM. 'This strategic funding agreement enables us to move rapidly toward the potential U.S. commercialization of ITM-11, subject to FDA approval, and provides flexibility for the development and expansion of our innovative pipeline of targeted radiopharmaceuticals across a broad range of indications.' 'With its vertically integrated approach that combines a profitable radioisotope manufacturing business with radiopharmaceutical pipeline development, we believe ITM is uniquely positioned to positively impact the precision oncology sector. We look forward to supporting ITM's continued growth and mission to bring innovative treatment options to people living with cancer,' said Sandip Agarwala, Managing Director and Head of Life Sciences at Blue Owl. About n.c.a. 177Lu-edotreotide (ITM-11)177Lu-edotreotide is a radiolabeled peptide conjugate that delivers beta radiation specifically to SSTR-positive tumor cells, sparing healthy organs and tissue. The drug candidate, delivered intravenously, is comprised of non-carrier-added Lutetium-177, a therapeutic β-emitting radioisotope, and edotreotide, a synthetic SSTR agonist. 177Lu-edotreotide was granted orphan drug designation in the E.U. and the U.S., and fast track designation in the U.S. for the treatment of GEP-NETs, based on positive results from a retrospective Phase 2 study with 177Lu-edotreotide. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. About Blue OwlBlue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives®. With $273 billion in assets under management as of March 31, 2025, Blue Owl invests across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Assets. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 1,200 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ Attachment 20250527_ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed FundsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
GARCHING / MUNICH, Germany and SYDNEY, May 19, 2025 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX 'Radiopharm'), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the signing of a supply agreement that will provide Radiopharm with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu), to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in Radiopharm's development pipeline. Under the terms of the agreement, Radiopharm will use ITM's n.c.a. 177Lu across its clinical pipeline, including in key programs such as RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 (HER2-targeting nanobody, Phase 1), and RV01 (B7-H3-targeting monoclonal antibody, preclinical), for the treatment of solid tumors. Coupled with the targeting molecules that are designed to deliver ITM's n.c.a. 177Lu directly to tumor sites, the radioisotope emits therapeutic beta radiation with the aim to destroy malignant cells in a highly precise and localized manner. 'Ensuring supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs,' said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. 'Lutetium-177 is required for three of our more advanced assets and this supply agreement with a radiopharmaceutical leader like ITM is another important step to ensure quality, reliability, and redundancy in our clinical development plans.' ITM's n.c.a. 177Lu is a market-approved, highly pure form of the beta-emitting radioisotope, Lutetium-177, that can be linked to tumor-specific targeting molecules for the treatment of various cancers and has been successfully used in numerous clinical and commercial radiopharmaceutical cancer treatments. ITM holds a U.S. Drug Master File (DMF) with the Food and Drug Administration (FDA) for n.c.a. 177Lu and has marketing authorization in the EU (brand name EndolucinBeta®). 'As the leading global manufacturer of non-carrier-added Lutetium-177, we are just as committed to supplying our global partners with high-quality medical radioisotopes as we are to supplying our own pipeline,' said Andrew Cavey, CEO of ITM. 'Supporting Radiopharm in the advancement of their therapeutic candidates reflects our shared dedication to delivering improved treatment options to people living with cancer.'About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. Radiopharm TheranosticsRadiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper. For more information:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Paul Hopper Executive Chairman P: +61 406 671 515 E: paulhopper@ MediaMatt WrightNWR CommunicationsP: +61 451 896 420E: matt@ ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
PET Tracers Market Trends, Growth Drivers and Future Opportunities
PET Tracers Market Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, May 19, 2025 (GLOBE NEWSWIRE) -- The global PET tracers market is poised for transformative growth, projected to rise from USD 1.7 billion in 2024 to approximately USD 4.3 billion by 2034, at a compound annual growth rate (CAGR) of 9.6%. Positron Emission Tomography (PET) tracers—radioactive compounds used in diagnostic imaging—are at the forefront of personalized medicine, aiding in accurate disease detection, staging, and monitoring of treatment efficacy. PET tracers enable molecular imaging at a cellular level and are particularly vital in oncology, neurology, and cardiology. Get a Sample PDF Brochure: With the rising prevalence of chronic diseases such as cancer and neurodegenerative disorders, coupled with advancements in radiochemistry and the approval of novel radiopharmaceuticals, the market is rapidly expanding. Regulatory support, increased radiopharmaceutical research, and broader applications in PET/CT and PET/MRI technologies further boost market potential. Market Dynamics Key Growth Drivers Surging Cancer Incidence Worldwide: PET tracers, especially Fluorodeoxyglucose F18 (FDG), remain the gold standard in oncology for tumor imaging, metastasis detection, and treatment monitoring. Rising global cancer rates are a significant catalyst for PET tracer demand. Technological Innovations in Molecular Imaging: Advances in PET/CT and PET/MRI systems have increased the precision and resolution of imaging, thereby expanding the use of tracers across therapeutic areas. Government and Regulatory Support: Agencies like the FDA, EMA, and IAEA are actively promoting radiopharmaceutical development, with faster approvals for diagnostic agents addressing unmet clinical needs. Rise in Geriatric Population and Chronic Diseases: The aging global population is more susceptible to Alzheimer's, Parkinson's, and cardiovascular conditions, where PET tracers play a critical role in early and accurate diagnosis. Increased Investments in Radiopharmaceutical R&D: Private and public sector collaborations have led to the emergence of novel tracers, expanding beyond traditional fluorodeoxyglucose and ammonia-based agents. Market Challenges Short Half-life of PET Tracers: Radioisotopes like F18 and N13 decay quickly, necessitating close proximity to cyclotron facilities or efficient logistical networks. High Operational Costs: Establishing and maintaining PET centers with tracer production units and regulatory compliance involves substantial financial outlay. Regulatory Hurdles and Licensing: Stringent rules around radioisotope handling, production, and distribution may delay market access, especially in emerging economies. Market Opportunities Expansion in Emerging Markets: Rising healthcare infrastructure and increasing awareness of early diagnosis in Asia-Pacific, Latin America, and the Middle East are creating new demand clusters. Targeted Radiotracers for Theranostics: The convergence of diagnostics and therapy (theranostics) is being driven by radiotracers designed for specific tumor markers or disease targets. AI-Integrated Imaging Platforms: The fusion of PET tracers with AI-driven diagnostics can revolutionize interpretation speed, image analysis accuracy, and clinical workflows. Buy Now : Market Segmentation By Product Type Fluorodeoxyglucose F18 (FDG): The most commonly used PET tracer, FDG highlights areas of increased glucose metabolism and is extensively used in cancer imaging, neurology, and infectious diseases. Ammonia N13: Primarily used in cardiac imaging to assess myocardial perfusion and viability. Its short half-life necessitates in-house or close-proximity production. Others: Choline C11: Used in prostate cancer imaging. Fluorothymidine F18 (FLT): Evaluates tumor proliferation. Fluorodopa F18: Applied in neuroimaging for Parkinson's and other movement disorders. New peptide-based radiotracers: For receptor-targeted imaging in endocrine and neuroendocrine tumors. By Application Oncology: The largest segment, accounting for over 60% of market revenue. PET tracers are critical in tumor detection, staging, radiation planning, and monitoring chemotherapy or immunotherapy response. Neurology: PET tracers like F-18 florbetapir and F-18 flortaucipir help in early diagnosis of Alzheimer's, tracking amyloid and tau protein buildup in the brain. Cardiology: PET tracers evaluate myocardial perfusion and metabolism, aiding in assessment of ischemic heart disease, cardiac sarcoidosis, and viability studies. Others: Infectious diseases: Tracking inflammation and response to antibiotics. Endocrinology: Imaging of parathyroid adenomas and neuroendocrine tumors. Psychiatry: Investigational use in imaging neurotransmitter systems. By End User Hospitals: Tertiary care and specialty hospitals with PET imaging capabilities are the largest consumers of PET tracers, especially in oncology departments. Diagnostic Centers: Independent imaging facilities are increasingly investing in PET/CT and PET/MRI setups due to rising demand and government incentives. Research Institutions: Leading in new tracer development, toxicity testing, and clinical trial imaging. Academic partnerships with pharmaceutical companies are on the rise. By Technology Novel Radiopharmaceuticals: Radiotracers specifically engineered for improved targeting, binding affinity, or imaging contrast. Includes tracers targeting prostate-specific membrane antigen (PSMA), somatostatin receptors, and HER2 markers. Radiolabeled Biomolecules: Includes peptides, antibodies, and ligands labeled with positron emitters for disease-specific targeting and enhanced tissue uptake. Others: Metabolic Tracers: Beyond FDG, new compounds that assess different metabolic pathways. Gene Reporter Tracers: Investigational agents for assessing gene expression in vivo. By Distribution Channel Direct Sales: Large hospitals, research institutions, and radiopharmaceutical companies procure directly from tracer manufacturers for consistent supply and custom synthesis. Distributors: Authorized regional players handle the logistics, regulatory compliance, and cold chain delivery of radiotracers to facilities lacking in-house cyclotrons. Online Sales: Gaining traction in developed regions for ordering non-radioactive precursor kits, instrumentation, and in some cases, same-day tracer delivery where infrastructure permits. Browse full Report – Regional Insights North America: Accounts for over 40% of global revenue, led by the U.S., which houses an extensive network of PET centers, cyclotron units, and FDA-approved radiopharmaceuticals. Canada follows with rising installations of hybrid PET/MRI systems. Europe: Germany, the UK, France, and the Netherlands lead due to high healthcare spending and robust research infrastructure. European initiatives such as Euro-BioImaging and EANM promote harmonization in PET imaging. Asia-Pacific: Expected to exhibit the fastest CAGR. China and India are investing in PET radiopharmacy units and academic PET research. Japan is already a pioneer in neuro-PET imaging and theranostics. Latin America: Brazil and Mexico are expanding nuclear medicine departments through public-private partnerships. Growth is driven by oncology programs and increasing medical tourism. Middle East & Africa: UAE, Saudi Arabia, and South Africa are emerging markets. Recent investments in precision medicine and radiotherapy have paved the way for PET tracer adoption. Competitive Landscape The PET tracers market is moderately consolidated, with a mix of radiopharmaceutical giants, cyclotron manufacturers, and research-focused biotech companies. Key Players Include: GE Healthcare: Provides a broad radiopharmaceutical portfolio including FDG, N13 ammonia, and gallium-based compounds. Siemens Healthineers: Offers radiotracer synthesis platforms and distribution partnerships. Cardinal Health: Operates one of the largest commercial radiopharmacy networks in North America. Lantheus Medical Imaging: Known for Flurpiridaz F18 and other cardiovascular tracers. Advanced Accelerator Applications (AAA): A Novartis company focused on oncology-specific PET tracers. Telix Pharmaceuticals: Specializes in theranostic agents for kidney, prostate, and brain cancers. Strategic Initiatives: Collaborations between pharma companies and PET imaging centers for trial-based tracer validation. Expansion of manufacturing sites to reduce tracer delivery times. Licensing of proprietary peptides and antibodies for tracer conjugation. Emerging Trends Theranostics Expansion: Using the same molecule for both imaging (with a PET isotope) and therapy (with a beta-emitter) is gaining clinical acceptance. AI-Driven Imaging Interpretation: Algorithms are being trained to quantify tracer uptake, predict outcomes, and flag anomalies in real-time. Kit-Based Tracer Synthesis: For remote locations, cold kits with long shelf life allow on-site preparation of PET tracers with minimal infrastructure. Growth of PET/MRI Fusion Imaging: Offers better soft-tissue contrast and lower radiation dose, enhancing tracer applications in neuro-oncology and pediatrics. This report is also available in the following languages : Japanese (PETトレーサー市場), Korean (PET 추적자 시장), Chinese (PET示踪剂市场), French (Marché des traceurs TEP), German (Markt für PET-Tracer), and Italian (Mercato dei traccianti PET), etc. Download Full PDF Sample Copy of Market Report @ Related Reports PET Cyclotrons Market The global PET cyclotron market is projected to reach approximately $1.2 billion in 2024, with a robust forecast indicating a market value of around $2.5 billion by 2034. This growth signifies a Compound Annual Growth Rate (CAGR) of approximately 8.1% during the period of 2025–2034. Sterile Procedure Trays Market The global sterile procedure trays market is projected to reach a value of approximately $5.2 billion in 2024, driven by the increasing demand for surgical procedures and the rising emphasis on infection control in healthcare settings. Between 2025 and 2034, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5%, leading to a projected value of about $10 billion by 2034. Surgical Operating Lights Market The global surgical operating lights market is valued at approximately $1.2 billion in 2024, driven by advancements in medical technology and increasing surgical procedures. Various sources project the market will grow to around $2.3 billion by 2034, indicating a robust Compound Annual Growth Rate (CAGR) of roughly 7.1% during the forecast period from 2025 to 2034. Metabolic Genetic Testing Market The global metabolic genetic testing market is poised for significant growth, with a projected market value of approximately $5.2 billion in 2024. It is anticipated to reach around $10.9 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 7.6% over the forecast period from 2025 to 2034. Clear Aligner Sheet Market The global clear aligner market is valued at approximately $7.5 billion, driven by increasing demand for aesthetic orthodontic solutions and advancements in dental technology. The market is projected to grow to around $13 billion by 2034, reflecting significant expansion opportunities. This growth trajectory suggests a Compound Annual Growth Rate (CAGR) of approximately 6.1% during the forecast period from 2025 to 2034 Cardiac Ultrasound Machine Market The global cardiac ultrasound machine market is valued at approximately $2.5 billion, driven by technological advancements and an increasing prevalence of cardiovascular diseases. The projected market value for 2034 is expected to reach around $4.5 billion, reflecting significant growth opportunities. The Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is estimated at 6.2%. Mobile C-arm Machine Market The global mobile C-arm machine market is poised for significant growth, currently valued at approximately $2.1 billion in 2024. By 2034, the market is expected to reach around $4.5 billion, driven by increasing demand for minimally invasive surgical procedures and advancements in imaging technology. This trajectory implies a robust Compound Annual Growth Rate (CAGR) of approximately 7.8% from 2025 to 2034. Post Surgery Compression Garment Market The global post-surgery compression garment market is valued at approximately $1.2 billion. This sector is projected to grow significantly, reaching about $2.5 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 7.5% from 2025 to 2034. Self-service Kiosks for Healthcare Market The global self-service kiosks market for healthcare is estimated to reach approximately $1.5 billion in 2024, with projections suggesting a steady growth trajectory, aiming for around $3 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of approximately 7.5% during the forecast period from 2025 to 2034. Cholesterol Assay Kits Market The global cholesterol assay kits market is valued at approximately $1.2 billion in 2024, driven by the rising prevalence of cardiovascular diseases and increased health awareness. Projected to reach around $2.1 billion by 2034, the market exhibits a Compound Annual Growth Rate (CAGR) of about 6.0% during the forecast period from 2025 to 2034. Temperature Screening Kiosk Market The global market for temperature screening kiosks is valued at approximately $1.2 billion in 2024, driven by heightened health awareness and demand for contactless solutions in public spaces. The market is projected to reach around $2.8 billion by 2034, reflecting a robust growth trajectory. This growth corresponds to a Compound Annual Growth Rate (CAGR) of 8.7% during the forecast period from 2025 to 2034. Zippered Band-Aid Market The global zippered Band-Aid market is valued at approximately $1.5 billion in 2024, with a projected market value anticipated to reach around $2.8 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of about 6.7% during the forecast period from 2025 to 2034. Hot Air Sterilizing Oven Market The global hot air sterilizing oven market is valued at approximately $320 million in 2024, with a projected market value of around $520 million by 2034, reflecting robust growth driven by increased demand for sterile processing in healthcare and pharmaceutical industries. From 2025 to 2034, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1%. Oral Solid Dosage(OSD) Equipment Market The global Oral Solid Dosage (OSD) equipment market is valued at approximately $6.2 billion in 2024, with a positive outlook to reach around $9.8 billion by 2034, translating to a robust Compound Annual Growth Rate (CAGR) of 5.7%. Soft Robot Grippers Market The global soft robot grippers market is valued at approximately $320 million, driven by advancements in automation and increasing demand for precision handling in various industries, including manufacturing, agriculture, and logistics. The market is anticipated to expand significantly at a compound annual growth rate (CAGR) of 18% from 2025 to 2034, potentially reaching a value of around $1.8 billion by the end of the forecast period. Medical Grade Air Compressor Market The global medical-grade air compressor market is valued at approximately USD 1.15 billion in 2024 and is projected to reach around USD 1.95 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period from 2025 to 2034. Vision Inspection System for Pharmaceutical Market The global vision inspection system market for pharmaceuticals is valued at approximately $1.2 billion in 2024, projected to reach around $2.4 billion by 2034. This growth reflects a robust compound annual growth rate (CAGR) of about 7.4% during the forecast period from 2025 to 2034. Blister Detection System Market The global blister detection system market is valued at approximately $2.1 billion in 2024, with a forecasted growth trajectory pointing towards a market value of around $3.8 billion by 2034. This reflects a robust Compound Annual Growth Rate (CAGR) of 6.1% during the 2025–2034 period. Nano-Silver Particle Market The global nano-silver particle market is valued at approximately $1.8 billion in 2024, with a projected compound annual growth rate (CAGR) of around 12% from 2025 to 2034, potentially reaching $5.65 billion by the end of the forecast period. Nano-Gold Particle Market The global nano-gold particle market is poised to reach a value of approximately $8.2 billion in 2024, driven by advancements in nanotechnology and increasing applications across various industries, including biomedical, electronics, and catalysis. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 12.4%, resulting in an estimated market value of around $22.0 billion by 2034. CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
India's Jubilant Pharmova posts surge in profit on demand for radiopharma medicines
(Reuters) -India's Jubilant Pharmova reported a surge in its fourth-quarter adjusted profit on Friday, driven by strong demand for its drugs with radioactive ingredients, used to treat cancer and other diseases. The drugmaker's consolidated profit before exceptional items and taxes rose 82% year-on-year to 2.09 billion rupees ($24.4 million) in the quarter ended March 31. Its net profit was 1.54 billion rupees in the quarter, compared with a year-ago loss of 586 million rupees, which included a 1.69-billion-rupee impairment charge for closing a plant in the U.S. Revenue rose 10% year-over-year to 19.29 billion rupees, lifted by a 9.5% jump in revenue from the radiopharma segment, which accounted for nearly 46% of the total revenue. The drugmaker, which makes and supplies radiopharmaceuticals used to diagnose and treat cancer and other diseases such as hyperthyroidism and lung diseases, has a network of 52 radio-pharmacies in the United States. This field is highly regulated and complex, thus limiting competition and benefiting companies such as Jubilant Pharmova, analysts said. Revenue from contract manufacturing, the company's second-biggest segment that makes sterile injectables, also jumped 33%. Revenue from its generics business, however, fell 22%. ($1 = 85.5930 Indian rupees) Sign in to access your portfolio
